Condition (MeSH)
Hepatitis, Alcoholic
ClinicalTrials.gov lists 107 trials for Hepatitis, Alcoholic or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
107 of the 107 trials are tagged with Hepatitis, Alcoholic itself; the rest are tagged with a narrower condition beneath it.
When did Hepatitis, Alcoholic trials start? (24)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 12
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 6 |
| 2024 | 7 |
| 2023 | 2 |
| 2022 | 6 |
| 2021 | 4 |
| 2020 | 4 |
| 2019 | 12 |
| 2018 | 4 |
| 2017 | 8 |
Showing 10 of 24 earlier years.
No forecast is made for this condition: it averages 4.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 8 trials still running at the 2026-10-09 snapshot; registered median of 35 months across 69 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Hepatitis, Alcoholic trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 4 |
| Phase 1/2 | 2 |
| Phase 2 | 21 |
| Phase 2/3 | 3 |
| Phase 3 | 16 |
| Phase 4 | 7 |
| Not applicable | 25 |
| Observational | 29 |
How many Hepatitis, Alcoholic trials are recruiting? (9)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 3 |
| Recruiting | 13 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 1 |
| Completed | 54 |
Showing 5 of 9 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Hepatitis, Alcoholic trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Conatus Pharmaceuticals Inc. | 2 |
| Durect | 2 |
| HepQuant, LLC | 2 |
Which drugs are being tested for Hepatitis, Alcoholic? (6)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| PREDNISOLONE | 9 |
| G-CSF | 5 |
| Pentoxifylline | 5 |
| Larsucosterol | 4 |
| Prednisone | 3 |
Showing 5 of 6 drugs.
Interventions as named in the registry (9)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Fecal Microbiota Transplantation | 4 |
| N Acetylcysteine | 4 |
| Standard Medical Therapy | 3 |
| Standard Medical Treatment | 2 |
| Rifaximine | 2 |
Showing 5 of 9 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Hepatitis, Alcoholic trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Acute Kidney Injury | 66 | 2 |
| All-cause mortality | 47 | 1 |
| Ascites | 26 | 10 |
| Pneumonia | 23 | 7 |
| Acute kidney injury | 22 | 6 |
Showing 5 of 10 adverse events.
Which publications cover Hepatitis, Alcoholic? (106)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| IL-1 Signal Inhibition in Alcohol-Related Hepatitis: A Randomized, Double-Blind, Placebo-Controlled Trial of Canakinumab. | Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association | 2025 | Yes |
| Larsucosterol for the Treatment of Alcohol-Associated Hepatitis. | NEJM evidence | 2025 | Yes |
| Rifaximin treatment in patients with severe alcohol-associated hepatitis: A multicenter, randomized controlled, open-label, pilot trial. | Annals of hepatology | 2025 | Yes |
| Safety, Pharmacokinetics, and Efficacy Signals of Larsucosterol (DUR-928) in Alcohol-Associated Hepatitis. | The American journal of gastroenterology | 2024 | Yes |
| Randomized trial of anakinra plus zinc vs. prednisone for severe alcohol-associated hepatitis. | Journal of hepatology | 2024 | Yes |
Showing 5 of 106 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.